Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
DOI:
https://doi.org/10.33448/rsd-v10i12.19989Keywords:
Sleep disorders; HIV; Depression; Antiretroviral therapy; Efavirenz; Dolutegravir; Atazanavir.Abstract
Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir.
References
Alves, R., Baptista, A. M., Moutinho, A., Moutinho, F., & Teixeira, J. (2013) VIH: aspectos neuropsiquiátricos da infecção e da terapêutica. Psilogos: Revista do Serviço de Psiquiatria do Hospital Fernando Fonseca, 11, 64-70.
Araujo, P. A. B., Sties, S. W., Wittkopf, P. G., Schmitt Netto, A., Gonzáles, A. I., Lima, D. P., Guimarães, S. N., Aranha, E. E., & De Carvalho, A. A. T. (2015). Pittsburgh sleep quality index for use in cardiopulmonary and metabolic rehabilitation. Rev Bras Med Esporte 21 (6).
Azevedo, R. L. W., Silva, E. A. A., Dionísio, L. R., & Saldanha, A. A. W. (2014) Trastornosafetivos/cognitivos associados à TARV e à qualidade de vida no contexto da Aids. Revista Interamericana de Psicologia/Interamerican Journal of Psychology (IJP), 48(2), 238-251.
Bertolazi, A. N., Fagondes, S. C., Hoff, L. S., Dartora, E. G., Miozzo, I. C., de Barba, M. E., & Barreto, S. S. (2011). Validation of the Brazilian Portuguese version of the Pittsburgh Sleep Quality Index. Sleep Med. 12(1):70-5. 10.1016/j.sleep.2010.04.020.
Brasil; ministério da saúde (ms); secretaria de vigilância em saúde. (2018) Protocolo clínico e diretrizes terapêuticas para manejo da infecção pelo HIV em adultos. http://www.aids.gov.br/pt-br/pub/2013/protocolo-clinico-e-diretrizes-terapeuticas-para-manejo-da-infeccao-pelo-hiv-em-adultos
Brew, B. J., Chan, P. (2014) Update on HIV dementia and HIV-associated neurocognitive disorders. Current neurology and neuroscience reports, 14(8), 468.
Cahn P, Pozniak A. L, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia C. B, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small C. B, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, & Min S; extended SAILING Study Team (2013). Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 382(9893):700-8.
Chang, J. L., Tsai, A. C., Musinguzi, N., Haberer, J. E., Boum, Y., Muzoora, C., Bwana, M., Martin, J. N., Hunt, P. W., Bangsberg, D. R., & Siedner, M. J. (2018) Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. Ann Intern Med. Aug 7;169(3):146-155.
Empana, J. P., Dauvilliers, Y., Dartigues, J. F., Ritchie, K., Gariepy, J., Jouven, X., Tzourio, C., Amouyel, P., Besset, A., & Ducimetiere, P. (2009) Excessive daytime sleepiness is an independent risk indicator for cardiovascular mortality in community-dwelling elderly: the three city study. Stroke. 40(4):1219-24.
Fettiplace, A., Stainsby, C., Winston, A., Givens, N., Puccini, S., Vannappagari, V., Hsu, R., Fusco, J., Quercia, R., Aboud, M., & Curtis, L. (2017). Psychiatric Symptoms in Patients Receiving Dolutegravir. Journal of acquired immune deficiency syndromes (1999), 74(4), 423–431.
Gutierrez, J., Tedaldi, E. M., Armon, C., Patel, V., Hart, R., & Buchacz, K. (2019). Sleep disturbances in HIV-infected patients associated with depression and high risk of obstructive sleep apnea. SAGE open medicine, 7.
Haziot, M., Barbosa Junior, S. P., Vidal, J. E., de Oliveira, F., & de Oliveira, A. (2015). Neuroimaging of HIV-associated neurocognitive disorders. Dementia & neuropsychologia, 9(4), 380–384.
Hsu, R., Fusco, J., Henegar, C., Mounzer, K., Wohlfeiler, M., Vannappagari, V., Aboud, M., Curtis, L., & Fusco, G. (2018). Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database (OPERA). Therapeutic advances in drug safety, 9(12), 675–686.
Huang, X., Li, H., Meyers, K., Xia, W., Meng, Z., Li, C., Bai, J., He, S., Cai, W., Huang, C., Liu, S., Wang, H., Ling, X., Ma,P., Tan, D., Wang, F., Ruan, L., Zhao, H., Wei, H., Liu, Y., Yu, J., Lu, H., Wang, M., Zhang, T., Chen, H. & Wu, H (2017). Burden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across China. Sci Rep 7, 3657.
Kamat, R, Cattie, J. E., Marcotte, T. D., Woods, S. P., Franklin, D. R., Corkran, S. H., Ellis, R. J., Grant, I., & Heaton, R. K. (2015) Incident major depressive episodes increase the severity and risk of apathy in HIV infection. J Affect Disord. 175:475-80.
Lee, K.A., Gay, C., Portillo, C.J., Coggins, T., Davis, H., Pullinger, C. R., & Aouizerat, B. E. (2012) Types of sleep problems in adults living with HIV/AIDS. J Clin Sleep Med. 8(1):67-75.
Malava, J. K., Lancaster, K. E., Hosseinipour, M. C., Rosenberg, N. E., O'Donnell, J. K., Kauye, F., Mbirimtengerenji, N., Chaweza, T., Tweya, H., Phiri, S., Pence, B. W., & Gaynes, B. N. (2018). Prevalence and correlates of probable depression diagnosis and suicidal ideation among patients receiving HIV care in Lilongwe, Malawi. Malawi medical journal: the journal of Medical Association of Malawi, 30(4), 236–242.
Molina J. M., Clotet B., Lunzen J. v., Lazzarin A., Cavassini M., Henry K., Kulagin V., Givens N., Oliveira C. F., Brennan C., on behalf of the FLAMINGO study team (2015). Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. The Lancet 2(4), E127-E136.
Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., & Solomon, T. (2014) Controversies in HIV-associated neurocognitive disorders. The Lancet Neurology, 13(11), 1139-1151.
Orrell, C., Hagins, D. P., Belonosova, E., Porteiro, N., Walmsley, S., Falcó, V., Man, C. Y., Aylott, A., Buchanan, A. M., Wynne, B., Vavro, C., Aboud, M., Smith, K. Y., & ARIA study team (2017). Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. The lancet. HIV, 4(12), e536–e546.
Santos, I. S., Tavares, B. F., Munhoz, T. N., de Almeida, L. S. P., da Silva, N. T. B., Tams, B. D., Patella, A. M., & Matijasevich, A. (2013) Sensibilidade e especificidade do Patient Health Questionnaire-9 (PHQ-9) entre adultos da população geral. Cadernos de Saúde Pública, 29, 1533-1543.
Santos, E. E. P., Ribeiro, A. C., Paula, C. C. & Padoin, S. M. M. (2020). From the discovery of diagnosis to antiretroviral treatment: phenomenological study with young people living with HIV. Research, Society and Development, 9(7): 1-16, e441974254.
Santos, G. S., Melo, G. C. de, Duprat, I. P., Brandão, T. M., & Silva, Y. T. da. (2021). Depressive symptoms in people living with the Human Immunodeficiency Virus. Research, Society and Development, 10(6), e14710615493.
Shikuma, C. M., Kohorn, L., Paul, R., Chow, D. C., Kallianpur, K. J., Walker, M., Souza, S., Gangcuangco, L., Nakamoto, B. K., Pien, F. D., Duerler, T., Castro, L., Nagamine, L., & Soll, B. (2018). Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy. HIV clinical trials, 19(4), 139–147.
Troncoso, F. T., & Conterno, L. O. (2015). Prevalence of neurocognitive disorders and depression in a Brazilian HIV population. Revista da Sociedade Brasileira de Medicina Tropical, 48(4), 390-398.
Vitoria, M., Hill, A., Ford, N., Doherty, M., Clayden, P., Venter, F., Ripin, D., Flexner, C., & Domanico, P. L. (2018) The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. Jul 31;32(12):1551-1561. 10.1097/QAD.0000000000001845.
Williams, D. W., Li, Y., Dastgheyb, R., Fitzgerald, K. C., Maki, P. M., Spence, A. B., Gustafson, D. R., Milam, J., Sharma, A., Adimora, A. A., Ofotokun, I., Fischl, M. A., Konkle-Parker, D., Weber, K. M., Xu, Y., & Rubin, L. H. (2020). Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV. J Neuroimmune Pharmacol. 16(1):181-194.
Walmsley, S., Baumgarten, A., Berenguer, J., Felizarta, F., Florence, E., Khuong-Josses, M. A., Kilby, J. M., Lutz, T., Podzamczer, D., Portilla, J., Roth, N., Wong, D., Granier, C., Wynne, B., & Pappa, K. (2015). Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. Journal of acquired immune deficiency syndromes (1999), 70(5), 515–519.
WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring - news release, https://www.who.int/publications/i/item/9789240031593
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Melissa Soares Medeiros; Liliane Nogueira Granjeiro; Yandra Mirelle Nogueira Alves; Jose Edvar di Castro Junior; Luan Victor Almeida Lima
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
